Biomarker Research in Musculoskeletal Disease

描述（由申请人提供）： 道格拉斯C. Bauer博士是加州大学旧金山分校弗朗西斯科的医学、流行病学和生物统计学副教授，作为一名研究人员、教育工作者和临床医生有着良好的记录。在1992年完成临床流行病学研究员培训后，Bauer博士与Steven Cummings博士一起获得了为期3年的职业发展指导奖。他目前是普通内科部的研究主任，是UCSF协调中心（UCSF CC）的核心教员。 候选人建议建立一个以患者为导向的研究计划，重点是在肌肉骨骼和衰老研究中使用生物标志物。该计划的目标是促进以患者为导向的研究在UCSF之间的医疗居民，研究员和初级教师，并提供初级研究人员有机会更好地了解生物标志物的方法和利用生物标志物在他们的研究。 利用UCSF的许多临床研究培训资源和通过UCSF CC提供给Bauer博士的几个大型骨质疏松症临床试验数据库，该计划的总体目标是：1）指导住院医师，临床研究员和初级教师进行以患者为导向的研究; 2）为希望在以患者为导向的肌肉骨骼研究中利用生物标志物的学员提供专业知识和机会，以及3）来加深我们对骨质疏松症生物标志物的理解。Bauer博士的研究计划的具体目标是：1）确定几种抗吸收治疗骨质疏松症的抗骨折疗效的差异，这些抗吸收治疗的定义是选定的生物标志物（包括雌二醇和骨转换标志物）的基线水平; 2）在阿仑膦酸钠、雷洛昔芬的临床试验中，比较骨转换生化标志物的变化是否足以作为骨折结局的替代物，和雌激素-孕酮;和3）通过骨密度的变化以及骨转换的生化标志物的变化来比较几种骨质疏松症治疗（包括阿仑膦酸钠、雷洛昔芬和雌激素-孕激素）的抗骨折作用的介导程度。 K24的资助将使鲍尔博士能够减少他的临床和行政责任，并将精力集中在促进和教授以患者为导向的研究上。

DESCRIPTION (provided by applicant): Douglas C. Bauer, MD is an Associate Professor of Medicine, and Epidemiology and Biostatistics at the University of California, San Francisco, with an established track record as a researcher, educator, and clinician. After completing fellowship training in clinical epidemiology in 1992, Dr Bauer undertook a 3 year mentored career development award with Dr. Steven Cummings. He is currently Director of Research for the Division of General Internal Medicine, and is a core faculty member of the UCSF Coordinating Center (UCSF CC). The candidate proposes building a program of patient-oriented research focused on the use of biomarkers in musculoskeletal and aging research. The objectives of the program are to promote patient-oriented research at UCSF among medical residents, fellows, and junior faculty, and to provide junior investigators with opportunities to better understand biomarker methodology and utilize biomarkers in their research. Using the many clinical research training resources available at UCSF and several large osteoporosis clinical trial databases available to Dr. Bauer through the UCSF CC, the overall aims of this program are: 1) to mentor medical residents, clinical research fellows, and junior faculty to conduct patient-oriented research; 2) to provide expertise and opportunities for mentees who wish to utilize biomarkers in patient-oriented musculoskeletal research and 3) to advance our understanding of biomarkers in osteoporosis. The specific aims of Dr. Bauer's research plan are: 1) To determine differences in the anti-fracture efficacy of several anti-resorptive treatments for osteoporosis defined by baseline levels of selected biomarkers, including estradiol and markers of bone turnover; 2) To compare the adequacy of change in biochemical markers of bone turnover to serve as a surrogate for fracture outcomes in clinical trials of alendronate, raloxifene, and estrogen-progestin; and 3) To compare the degree of mediation of the anti-fracture effect of several osteoporosis treatments, including alendronate, raloxifene, and estrogen-progestins, by change in BMD as well as change in biochemical markers of bone turnover. Funding of this K24 will allow Dr. Bauer to reduce his clinical and administrative responsibilities, and focus his efforts on promoting and teaching patient-oriented research.